YU28700A - Use of thiazolidinediones for the treatment of hyperglycaemia - Google Patents
Use of thiazolidinediones for the treatment of hyperglycaemiaInfo
- Publication number
- YU28700A YU28700A YU28700A YU28700A YU28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- hyperglycaemia
- treatment
- thiazolidinediones
- mammal
- pharmaceutically acceptable
- Prior art date
Links
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 231100000489 sensitizer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range of from > 126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721692.3A GB9721692D0 (en) | 1997-10-13 | 1997-10-13 | Novel treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU28700A true YU28700A (en) | 2003-10-31 |
Family
ID=10820481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU28700A YU28700A (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1023057A1 (en) |
| JP (1) | JP2001519383A (en) |
| KR (1) | KR20010024482A (en) |
| CN (1) | CN1281358A (en) |
| AP (1) | AP1223A (en) |
| AU (1) | AU9547198A (en) |
| BG (1) | BG104405A (en) |
| BR (1) | BR9815220A (en) |
| CA (1) | CA2305289A1 (en) |
| CZ (1) | CZ20001298A3 (en) |
| EA (1) | EA200000418A1 (en) |
| GB (1) | GB9721692D0 (en) |
| HR (1) | HRP20000256A2 (en) |
| HU (1) | HUP0003673A3 (en) |
| ID (1) | ID24439A (en) |
| IL (1) | IL135515A0 (en) |
| NO (1) | NO20001897L (en) |
| OA (1) | OA11519A (en) |
| PL (1) | PL339804A1 (en) |
| SK (1) | SK5322000A3 (en) |
| TR (1) | TR200000957T2 (en) |
| UA (1) | UA66809C2 (en) |
| WO (1) | WO1999018944A1 (en) |
| YU (1) | YU28700A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| OA11579A (en) * | 1998-07-21 | 2004-06-01 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing apoptosis. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2137915T3 (en) * | 1987-09-04 | 2000-01-01 | Beecham Group Plc | DERIVATIVES OF TIAZOLIDINDIONA SUBSTITUTED. |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
-
1997
- 1997-10-13 GB GBGB9721692.3A patent/GB9721692D0/en not_active Ceased
-
1998
- 1998-10-12 PL PL98339804A patent/PL339804A1/en unknown
- 1998-10-12 HU HU0003673A patent/HUP0003673A3/en unknown
- 1998-10-12 EP EP98949088A patent/EP1023057A1/en not_active Withdrawn
- 1998-10-12 IL IL13551598A patent/IL135515A0/en unknown
- 1998-10-12 SK SK532-2000A patent/SK5322000A3/en unknown
- 1998-10-12 ID IDW20000670A patent/ID24439A/en unknown
- 1998-10-12 CZ CZ20001298A patent/CZ20001298A3/en unknown
- 1998-10-12 AP APAP/P/2000/001788A patent/AP1223A/en active
- 1998-10-12 HR HR20000256A patent/HRP20000256A2/en not_active Application Discontinuation
- 1998-10-12 TR TR2000/00957T patent/TR200000957T2/en unknown
- 1998-10-12 AU AU95471/98A patent/AU9547198A/en not_active Abandoned
- 1998-10-12 CN CN98812016A patent/CN1281358A/en active Pending
- 1998-10-12 OA OA1200000107A patent/OA11519A/en unknown
- 1998-10-12 JP JP2000515579A patent/JP2001519383A/en active Pending
- 1998-10-12 KR KR1020007003935A patent/KR20010024482A/en not_active Ceased
- 1998-10-12 BR BR9815220-3A patent/BR9815220A/en not_active Application Discontinuation
- 1998-10-12 EA EA200000418A patent/EA200000418A1/en unknown
- 1998-10-12 CA CA002305289A patent/CA2305289A1/en not_active Abandoned
- 1998-10-12 YU YU28700A patent/YU28700A/en unknown
- 1998-10-12 UA UA2000042049A patent/UA66809C2/en unknown
- 1998-10-12 WO PCT/GB1998/003067 patent/WO1999018944A1/en not_active Application Discontinuation
-
2000
- 2000-04-12 NO NO20001897A patent/NO20001897L/en not_active Application Discontinuation
- 2000-05-05 BG BG104405A patent/BG104405A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL135515A0 (en) | 2001-05-20 |
| SK5322000A3 (en) | 2000-09-12 |
| HUP0003673A3 (en) | 2001-12-28 |
| EP1023057A1 (en) | 2000-08-02 |
| CZ20001298A3 (en) | 2001-08-15 |
| WO1999018944A1 (en) | 1999-04-22 |
| CA2305289A1 (en) | 1999-04-22 |
| BG104405A (en) | 2000-12-29 |
| AP1223A (en) | 2003-11-13 |
| UA66809C2 (en) | 2004-06-15 |
| JP2001519383A (en) | 2001-10-23 |
| AU9547198A (en) | 1999-05-03 |
| NO20001897D0 (en) | 2000-04-12 |
| CN1281358A (en) | 2001-01-24 |
| KR20010024482A (en) | 2001-03-26 |
| HUP0003673A2 (en) | 2001-10-28 |
| PL339804A1 (en) | 2001-01-02 |
| TR200000957T2 (en) | 2000-08-21 |
| EA200000418A1 (en) | 2000-10-30 |
| OA11519A (en) | 2004-02-09 |
| BR9815220A (en) | 2000-11-14 |
| GB9721692D0 (en) | 1997-12-10 |
| NO20001897L (en) | 2000-06-09 |
| HRP20000256A2 (en) | 2000-12-31 |
| ID24439A (en) | 2000-07-20 |
| AP2000001788A0 (en) | 2000-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1787646A3 (en) | Novel method of treatment | |
| PL325825A1 (en) | Microemulsion for use as a carrier for administering active compounds | |
| YU37301A (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| EP1127579A3 (en) | Method for increasing bioavailability of oral pharmaceutical compositions | |
| AU3215597A (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
| EP2305251A3 (en) | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder | |
| CA2352552A1 (en) | Treatment of erectile dysfunction | |
| CA2339218A1 (en) | Methods and compositions for increasing insulin sensitivity | |
| WO1999004772A3 (en) | Use of levobupivacaine | |
| MY106528A (en) | Method of treating impotence. | |
| BG104059A (en) | Diabetes treatment with rosiglytazone and insulin | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| CA2350659A1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
| CA2190837A1 (en) | Transdermal delivery of anti-epileptic drugs | |
| BG104058A (en) | Diabetes treatment with thiazolydindion and sulphonylurea | |
| EP1023901A4 (en) | Ameliorant for hepatitis c remedial effect and application thereof | |
| AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
| YU28700A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
| BG101884A (en) | Salts of the clavulanic acid | |
| NZ503862A (en) | Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia | |
| WO2002041841A3 (en) | Compositions for adhesion prevention | |
| WO2000010590A3 (en) | Cancer treatment | |
| MY118982A (en) | Method of reducing tissue damage associated with ischemia | |
| WO1999033454A3 (en) | S-procyclidine for treating urinary incontinence |